This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Alexion's Ultomiris Gets FDA Approval for New Formulation
by Zacks Equity Research
Alexion (ALXN) gets FDA approval for Ultomiris 100 mg/mL, a new advanced formulation for the treatment of adults with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Why the Earnings Surprise Streak Could Continue for Alexion (ALXN)
by Zacks Equity Research
Alexion (ALXN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Stock Market News for Oct 8, 2020
by Zacks Equity Research
Benchmarks closed sharply higher on Wednesday after President Donald Trump tweeted to provide support to airlines and signaled a scope for further stimulus measures.
Alexion (ALXN) in Focus: Stock Moves 7.9% Higher
by Zacks Equity Research
Alexion (ALXN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Biotech Stock Roundup: ALXN to Raise Guidance, BMY to Buy MYOK & Other Updates
by Zacks Equity Research
The biotech sector remains in focus with regulatory, acquisition and other pipeline updates.
Alexion Plans to Raise 2020 Sales View, Buy Back $3B Shares
by Zacks Equity Research
Alexion (ALXN) announces plans to increase its 2020 sales guidance by more than $200 million and buy back $3 billion of stock.
Alexion's Ultomiris Gets Approval in Japan for Rare Disease
by Zacks Equity Research
Alexion's (ALXN) Ultomiris gets approval in Japan for the treatment of adults and children living with atypical hemolytic uremic syndrome.
Alexion's New Formulation of Ultomiris Gets CHMP Backing
by Zacks Equity Research
Alexion (ALXN) gets a positive opinion from the CHMP recommending marketing authorization for a new 100 mg/mL intravenous advanced formulation of Ultomiris in the EU.
Apellis Submits Pegcetacoplan Applications to FDA and EMA
by Zacks Equity Research
Apellis (APLS) submits an NDA to the FDA and an MAA to the European Medicines Agency for pegcetacoplan for the treatment of paroxysmal nocturnal hemoglobinuria.
Alexion & Caelum Begin Studies on CAEL-101 in AL Amyloidosis
by Zacks Equity Research
Alexion (ALXN) and partner Caelum Biosciences begin phase III studies on CAEL-101 in AL amyloidosis.
Alexion Pharmaceuticals (ALXN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Alexion Pharmaceuticals (ALXN) closed at $112.97 in the latest trading session, marking a +1.3% move from the prior day.
Alexion (ALXN) Catches Eye: Stock Jumps 6.8%
by Zacks Equity Research
Alexion (ALXN) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Novartis Announces Positive Data on PNH & Cholesterol Drugs
by Zacks Equity Research
Novartis (NVS) announces new positive data on its PNH drug, LNP023, and an investigational cholesterol-lowering treatment, inclisiran.
Why Is Alexion (ALXN) Up 2.1% Since Last Earnings Report?
by Zacks Equity Research
Alexion (ALXN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Immunovant Up on Positive Data From Myasthenia Gravis Study
by Zacks Equity Research
Immunovant's (IMVT) myasthenia gravis candidate, IMVT-1401, meets endpoints in a mid-stage study.
Gilead (GILD) Gets CRL From FDA for Rheumatoid Arthritis Drug
by Zacks Equity Research
Gilead (GILD) suffers a setback as the FDA issues a CRL for its rheumatoid arthritis drug.
Gilead Expands Collaboration With Tango for Cancer Therapies
by Zacks Equity Research
Gilead (GILD) expands its partnership with biotech company, Tango, for innovative targeted immune evasion cancer therapies.
Roche Gets FDA Nod for Nervous System Disorder Drug Enspryng
by Zacks Equity Research
Roche (RHHBY) obtains FDA approval for NMOSD drug under the brand name, Enspryng.
How Will Biotech ETFs React to Q2 Earnings Release?
by Sweta Jaiswal, FRM
Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their Q2 earnings releases amid the coronavirus crisis.
Alexion (ALXN) Beats on Q2 Earnings & Sales, Ups '20 Guidance
by Zacks Equity Research
Alexion (ALXN) beats on earnings and sales in the second quarter of 2020.
Alexion Pharmaceuticals (ALXN) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Alexion (ALXN) delivered earnings and revenue surprises of 21.96% and 14.12%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Big Drug Stock Q2 Earnings on Jul 30: LLY, GILD, VRTX & More
by Kinjel Shah
Let us take a look at five big drug/biotech companies, GILD, LLY, VRTX, ALXN, and AZN, gearing up for their earnings release.
Sorrento (SRNE) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Sorrento (SRNE) will provide updates on its drugs and revenues when it releases second-quarter 2020 results.
Nabriva (NBRV) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Nabriva (NBRV) will provide updates on its drugs and revenues when it releases second-quarter 2020 results.
Why Earnings Season Could Be Great for Alexion (ALXN)
by Zacks Equity Research
Alexion (ALXN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.